Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 16/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.46 |
| ▸ | AURKC | Q9UQB9 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13221382 | 0.92 | JAK2 (0.51) | JAK2HDAC1AURKAAURKBAURKC | |
| SCHEMBL13175629 | 0.85 | JAK2 (0.61) | JAK2AURKAAURKB | |
| SCHEMBL13221384 | 0.80 | JAK2 (0.49) | JAK2HDAC1AURKAAURKBAURKC | |
| SCHEMBL13221381 | 0.79 | AURKA (0.41) | JAK2AURKAAURKB | |
| SCHEMBL12922948 | 0.77 | JAK2 (0.67) | JAK2AURKAAURKBAURKC | |
| SCHEMBL15759458 | 0.75 | JAK2 (0.64) | JAK2HDAC1AURKAAURKBAURKC | |
| SCHEMBL12314108 | 0.75 | JAK2 (0.64) | JAK2AURKAAURKBAURKC | |
| SCHEMBL2916720 | 0.75 | SYK (0.41) | JAK2AURKAAURKB | |
| SCHEMBL13221645 | 0.74 | AURKA (0.45) | JAK2HDAC1AURKAAURKBAURKC | |
| SCHEMBL12102305 | 0.72 | JAK2 (0.59) | JAK2HDAC1AURKAAURKBAURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1812439-B2 | KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-12-06 | — | — | EP | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| US-8288536-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-10-16 | — | — | US | disclosed |
| EP-1812439-B1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2010-09-01 | — | — | EP | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-20100216765-A1 | KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-26 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
| US-7713973-B2 | Kinase inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216765-A1 | KINASE INHIBITORS | MAP3K20, MAP3K19, MAP3K1 | JAK2 55/4885HDAC1 1131/4885AURKA 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.